Beyond allopurinol and the well-established uricosuric drugs, several other agents can decrease serum uric acid (SUA) levels, such as losartan, fenofibrate and some non-steroidal anti-inflammatory drugs (NSAIDs). Some of these drugs increase renal urate excretion. Hyperuricaemia and gout are common problems (at least 1% of Western men are affected by gout). Raised SUA levels increase the incidence of acute gout and renal calculi. Hyperuricaemia may also predict an increased risk of vascular events. Therefore, lowering SUA levels is of clinical relevance. In this review we consider the effect on SUA levels of drugs that are prescribed for indications other than treating hyperuricaemia. These drugs may obviate the need for specific treatment (e.g. allopurinol) aimed at lowering SUA levels. Furthermore, because hyperuricaemic patients may already be on several drugs (e.g. due to associated dyslipidaemia, hypertension and/or arthritis) compliance may be improved by avoiding additional medication. The potential for adverse effects associated with polypharmacy would also be decreased.
Keywords: Uric acid, urate, uricosuric, fenofibrate, losartan, NSAID, diuretic, atorvastatin
Psoriasis vulgaris and Psoriasis pustulosa – Epidemiology, Quality of Life, Comorbidities and Treatment
Current Rheumatology Reviews Arterial Hypertension and Multiple Myeloma: Physiopathology and Cardiovascular Risk and ‘Practical’ Indications in Patients Receiving Carfilzomib
Current Hypertension Reviews Racial Differences in Gray Matter Integrity by Diffusion Tensor in Black and White Octogenarians
Current Alzheimer Research The ONTARGET Trial Programme: Facts and Lessons
Current Hypertension Reviews The Effects of Angiotensin II Signaling Blockade on Platelet Activity in Subjects with Hypertension
Current Hypertension Reviews Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Management of Erectile Dysfunction: An Under-Recognition of Hypertension
Current Pharmaceutical Design Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?
Current Molecular Pharmacology Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews ATP-Sensitive K+ Channel Openers: Old Drugs with New Clinical Benefits for the Heart
Current Vascular Pharmacology Insulin Resistance and Postprandial Hyperglycemia the Bad Companions in Natural History of Diabetes: Effects on Health of Vascular Tree
Current Diabetes Reviews Anthropometric Correlation with Metabolic Syndrome in Sarajevo Population
Endocrine, Metabolic & Immune Disorders - Drug Targets Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied
Recent Patents on Anti-Cancer Drug Discovery The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design Tissue Factor and Hypertension
Current Hypertension Reviews Snake Venom Peptides and Low Mass Proteins: Molecular Tools and Therapeutic Agents
Current Medicinal Chemistry Development of Nitrendipine Nanoliposome for Transdermal Drug Delivery: Preparation, Characterization and Permeation Studies
Drug Delivery Letters The Large and Growing Burden of Stroke
Current Drug Targets 2-Indolinone Derivatives as Potent Urease Inhibitors
Letters in Drug Design & Discovery